LGD-4665, an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies. Research demonstrated that LGD-4665 was well-tolerated with an excellent safety profile. Multiple phase-II studies in thrombocytopenic patients due to ITP, Hep-C and MDS with daily and weekly dosing regimens, as well as additional Phase-I pharmacology studies in healthy volunteers are underway.